TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29095521

Group type: EXPERIMENTAL
Intervention: Cholecalciferol/Calcium
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Cholecalciferol/Placebo
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Calcium/Placebo
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Double-Placebo
Number of subjects: 228
Study: 27815079

Group type: EXPERIMENTAL
Intervention: AnisEncap (enteric coated capsules of anise oil)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Colpermin® (active control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AnisEncap
Number of subjects: 120
Study: 24407551

Group type: EXPERIMENTAL
Intervention: RXU (RelyX Unicem 3MESPE-RXU) without enamel etching
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: RXU + E (RelyX Unicem 3MESPE-RXU with selective enamel etching)
Number of subjects: 34

Group type: COMPARATOR
Intervention: RXU
Number of subjects: 34

Group type: COMPARATOR
Intervention: RXU + E
Number of subjects: 34
Study: 23270200

Group type: EXPERIMENTAL
Intervention: tazarotene foam 0.1%
Number of subjects: 97

Group type: COMPARATOR
Intervention: vehicle foam
Number of subjects: 97

Group type: COMPARATOR
Intervention: no foam (blank patch)
Number of subjects: 97
Study: 15946913

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12006420

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg twice daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9614778

Group type: EXPERIMENTAL
Intervention: Dopamine (4 micrograms/kg/minute, Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dobutamine (4 micrograms/kg/minute, Group B)
Number of subjects: 20
Study: 7897035

Group type: EXPERIMENTAL
Intervention: Early-onset dysthymia
Number of subjects: 187

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Episodic major depression
Number of subjects: 187
Study: 2515593

Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g b.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 356252

Group type: EXPERIMENTAL
Intervention: Inhaled RS 7540 (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled RS 7540 (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31899185

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study: 29945404

Group type: EXPERIMENTAL
Intervention: Pi needle
Number of subjects: 278

Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 278
Study: 27217047

Group type: EXPERIMENTAL
Intervention: Tacrolimus with azole antifungal agents (AZ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tacrolimus without azole antifungal agents (AZ)
Number of subjects: 24
Study: 25015020

Group type: EXPERIMENTAL
Intervention: Physics forceps
Number of subjects: 54

Group type: COMPARATOR
Intervention: Universal extraction forceps
Number of subjects: 54
Study: 22250191

Group type: EXPERIMENTAL
Intervention: Selective BRAF inhibitors
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Analgesic and anti-inflammatory treatment (e.g., etoricoxib)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dose reduction of BRAF inhibitor
Number of subjects: 2
Study: 20531011

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 245
Study: 17645554

Group type: EXPERIMENTAL
Intervention: Sulphonylurea treatment in addition to dietary regulation and increased exercise
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 154
Study: 15955935

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 1,500 mg/day
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 150 mg/day
Number of subjects: 593

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 600 mg/day
Number of subjects: 593
Study: 11839708

Group type: EXPERIMENTAL
Intervention: Adrenaline injection plus heater probe thermocoagulation
Number of subjects: 1144
Study: 10405498

Group type: EXPERIMENTAL
Intervention: Adderall (single dose)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Methylphenidate (2 daily doses)
Number of subjects: 84
Study: 7749423

Group type: EXPERIMENTAL
Intervention: High-CHO diet of 10.52 +/‐ 0.57 g/kg body mass/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal CHO intake of 6.15 +/‐ 0.23 g/kg body mass/day
Number of subjects: 8
Study: 2309227

Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine (20 ml of 0.25% bupivacaine for 48 hours)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bupivacaine intercostal block
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cryofreezing of intercostal nerves
Number of subjects: 54
Study: 398485

Group type: EXPERIMENTAL
Intervention: Ampicillin (50 mg/kg/day in 4 divided doses for 5 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cefaclor (50 mg/kg/day in 3 divided doses for 5 days)
Number of subjects: 54
Study: 31808786

Group type: EXPERIMENTAL
Intervention: Informational treatment about opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 30714749

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT) plus treatment as usual (TAU)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 181
Study: 28345762

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (LCD) (≤50 g/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High carbohydrate diet (HCD) (≥250 g/d)
Number of subjects: 10
Study: 25087012

Group type: EXPERIMENTAL
Intervention: Family psychosocial intervention
Number of subjects: 50
Study: 24151390

Group type: EXPERIMENTAL
Intervention: Anisodamine (10 mg every 8 hours for 2 weeks)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control (0.9% isotonic saline for 2 weeks)
Number of subjects: 197
Study: 21208340

Group type: EXPERIMENTAL
Intervention: Minilaparotomy hysterectomy (≤5 cm incision)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard abdominal hysterectomy (>6 cm incision)
Number of subjects: 98
Study: 19751822

Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins E and C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline plasma ascorbic acid concentrations
Number of subjects: 20
Study: 17243700

Group type: EXPERIMENTAL
Intervention: Tangerine sauce (150 g containing 15 g of corn oil, 13 mg of lycopene)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-beta-carotene sauce (150 g containing 15 g of corn oil, 17 mg of total beta-carotene, 4 mg of lycopene)
Number of subjects: 12
Study: 14722172

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 micro g kg(‐1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caudal clonidine 2 micro g kg(‐1)
Number of subjects: 46
Study: 11560737

Group type: EXPERIMENTAL
Intervention: Collaboration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed methods evaluations
Number of subjects: 0
Study: 9763070

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study: 7844427

Group type: EXPERIMENTAL
Intervention: Secnidazole
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Ornidazole
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 415
Study: 3287973

Group type: EXPERIMENTAL
Intervention: 2 g cefotetan as a single prophylactic dose
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 1 g cefotetan as a single dose
Number of subjects: 260

Group type: COMPARATOR
Intervention: 2 g cefoxitin every 6 hours for a maximum of 4 doses
Number of subjects: 260
Study: 30294873

Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI) through the Pediatric Appropriate Use of Echocardiography (PAUSE) study
Number of subjects: 7781

Group type: COMPARATOR
Intervention: Post-Educational Intervention (post-EI)
Number of subjects: 7781

Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI)
Number of subjects: 7781
Study: 28162887

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26233827

Group type: EXPERIMENTAL
Intervention: Nicotine administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pre- and post-test values of heart rate, blood pressure, Visual Analogue Scale for fear or discomfort
Number of subjects: 20
Study: 24244339

Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine (10^9, 10^10, 5X10^10, 10^11 vp) administered on days 0, 28, and 84
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 48
Study: 20580251

Group type: EXPERIMENTAL
Intervention: IDON plus resistance exercise (NS + EX)
Number of subjects: 32

Group type: COMPARATOR
Intervention: IDON (NS) alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 32
Study: 18347653

Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric activations (MVIA) in LBP group
Number of subjects: 20

Group type: COMPARATOR
Intervention: MVIA force, right and left ULES, and LLES EMG in control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MVIA force, right and left ULES, and LLES EMG in LBP group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EMG of biceps femoris (BF) in both groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance at 100% HAT in LBP group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Higher percentages of HAT in control group
Number of subjects: 20
Study: 17168161

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Various brain electrostimulation procedures
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Different surgical techniques
Number of subjects: 692

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 692
Study: 14748475

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate treatment (200 mg/day for 2 weeks per 3 months)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alendronate treatment (5 mg/day)
Number of subjects: 50
Study: 11040231

Group type: EXPERIMENTAL
Intervention: Pima Indians
Number of subjects: 119

Group type: COMPARATOR
Intervention: Whites
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both ethnic groups
Number of subjects: 119
Study: 8642881

Group type: EXPERIMENTAL
Intervention: Nocturnal nasal ventilation (NNV) using a bilevel positive airway pressure (PAP) device set to deliver an inspiratory pressure of 10 cm H2O and a minimal expiratory pressure of 2 cm H2O.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham treatment using a bilevel positive airway pressure (PAP) device set to deliver an inspiratory pressure of 0 cm H2O and a minimal expiratory pressure of 2 cm H2O.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nocturnal nasal ventilation (NNV)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nocturnal nasal ventilation (NNV) and Sham treatment
Number of subjects: 13
Study: 1505287

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at night (2200 hr)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg three times a day (1800, 0800 and 1200 hr)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 6098223

Group type: EXPERIMENTAL
Intervention: Hand lotion containing 2% glutaric acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30561129

Group type: EXPERIMENTAL
Intervention: Xerostom® toothpaste and mouthwash (used 3 times/day for 28 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control products (used 3 times/day for 28 days)
Number of subjects: 24
Study: 31191847

Group type: EXPERIMENTAL
Intervention: Intraperitoneal incision repair
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Uterine exteriorization for incision repair
Number of subjects: 1028
Study: 26690292

Group type: EXPERIMENTAL
Intervention: Contingency management intervention (escalating monetary vouchers for smoking reduction targets)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Contingency management intervention
Number of subjects: 118
Study: 24570280

Group type: EXPERIMENTAL
Intervention: Older patients with sCJD
Number of subjects: 73

Group type: COMPARATOR
Intervention: Younger patients with sCJD
Number of subjects: 73
Study: 22481650

Group type: EXPERIMENTAL
Intervention: Vegetal biomembrane
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fibrase(®) (CONTROL)
Number of subjects: 21
Study: 21212672

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 17324127

Group type: EXPERIMENTAL
Intervention: Automated cutting needles
Number of subjects: 502

Group type: COMPARATOR
Intervention: Aspiration technique
Number of subjects: 502
Study: 16310435

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 2708
Study: 11383587

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional food‐borne beneficial bacteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biotechnology‐based products
Number of subjects: 0
Study: 9822501

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 as a 0.5-mg intracervical gel (Prepidil) with immediate oxytocin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prostaglandin E2 as a 10-mg controlled-release vaginal insert (Cervidil) with delayed oxytocin
Number of subjects: 70
Study: 7927956

Group type: COMPARATOR
Intervention: Ramipril 2.5 mg
Number of subjects: 624

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg plus Hydrochlorothiazide 12.5 mg
Number of subjects: 624
Study: 2913132

Group type: EXPERIMENTAL
Intervention: Albuterol repeat‐action tablets with a high fat content breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Albuterol repeat‐action tablets without food
Number of subjects: 12
Study: 163848

Group type: EXPERIMENTAL
Intervention: Polymyxin aerosol (2.5 mg/kg body wt/day in six divided doses)
Number of subjects: 744

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Polymyxin aerosol
Number of subjects: 744
Study: 395129

Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 22
Study: 31443716

Group type: EXPERIMENTAL
Intervention: OM-85 for 3 months
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: OM-85 for 6 months
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 288
Study: 28537001

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol fixed‐dose combination (FDC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 180
Study: 27503566

Group type: EXPERIMENTAL
Intervention: TRPV1 agonist (capsaicin 1 × 10(−5) M)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Transcutaneous sensory electrical stimulation (TSES) (Intelect VitalStim, biphasic pulses, 300 μs, 80 Hz)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (TRPV1 and TSES)
Number of subjects: 38
Study: 25171815

Group type: EXPERIMENTAL
Intervention: Skim Milk (SM)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Carbohydrate/Electrolyte Solution (CES)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 38
Study: 22996098

Group type: EXPERIMENTAL
Intervention: Hands-on training (group 1, n=103)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Demonstration training (group 2, n=100)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Hands-on training (group 1, n=67) after 72 hours
Number of subjects: 203

Group type: COMPARATOR
Intervention: Demonstration training (group 2, n=60) after 72 hours
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Hands-on training (group 1)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Demonstration training (group 2)
Number of subjects: 203
Study: 19788472

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 17150023

Group type: EXPERIMENTAL
Intervention: ID-KLH vaccine plus granulocyte-macrophage colony-stimulating factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BiovaxID plus granulocyte-macrophage colony-stimulating factor vaccination
Number of subjects: 0
Study: 15116260

Group type: EXPERIMENTAL
Intervention: Pravastatin (HMG CoA reductase inhibitor)
Number of subjects: 759

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 759
Study: 11603956

Group type: EXPERIMENTAL
Intervention: Copper dose of 2 mg Cu/L
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Copper dose of 4 mg Cu/L
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Copper dose of 6 mg Cu/L
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Copper dose of 8 mg Cu/L
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (0 mg Cu/L)
Number of subjects: 179
Study: 9557622

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy for ALL
Number of subjects: 16

Group type: COMPARATOR
Intervention: Influenza virus vaccine (1996-1997)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: B/T lymphocyte ratio during chemotherapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serum immunoglobulin levels
Number of subjects: 16
Study: 11271343

Group type: COMPARATOR
Intervention: Long-term steroid therapy (0.1 mg/kg per day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 46
Study: 2651949

Group type: COMPARATOR
Intervention: Furosemide (200 mg IV every 6 hours for 4 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Furosemide (200 mg IV every 6 hours) with dopamine (1 microgram/kg/min for 4 days)
Number of subjects: 23
Study: 1124717

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol (increasing doses)
Number of subjects: 19
Study: 31537327

Group type: EXPERIMENTAL
Intervention: CRT-D with a reduction in LVESV >35% in patients with LBBB
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: CRT-D with a reduction in LVESV ≤35% in patients with LBBB
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: CRT-D in patients without LBBB
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: CRT-D patients without LBBB with least reverse remodeling (quartile 1)
Number of subjects: 1436
Study: 28757104

Group type: EXPERIMENTAL
Intervention: Bipolar electric energy (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasonic advanced energy (Harmonic®) (group B)
Number of subjects: 40
Study: 26545263

Group type: EXPERIMENTAL
Intervention: Increases in social stress when with classmates, during weekdays, and in the morning.
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Loneliness as a moderating factor.
Number of subjects: 278
Study: 23639514

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (DEX, 0.5 μg/kg; n = 18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal saline (CON; n = 19)
Number of subjects: 37
Study: 21286241

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study: 19706631

Group type: EXPERIMENTAL
Intervention: sub-Tenon's block
Number of subjects: 200

Group type: COMPARATOR
Intervention: i.v. fentanyl
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 200
Study: 17061999

Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg plus full-dose cyclosporine (FDC)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: FTY720 5.0 mg plus reduced-dose cyclosporine (RDC)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) plus full-dose cyclosporine (FDC)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: FTY720 5.0 mg
Number of subjects: 668

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 668
Study: 15055565

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patanol (olopatadine 0.1%)
Number of subjects: 0
Study: 10933918

Group type: EXPERIMENTAL
Intervention: Cationic liposome (EDMPC cholesterol) complexed with hCFTR cDNA
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8833678

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intensive treatment approaches
Number of subjects: 30
Study: 1330437

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6100
Study: 2414023

Group type: EXPERIMENTAL
Intervention: Cisplatinum
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cisplatinum and Bleomycin (combined treatment)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 116